Biotech Active Stocks: Pfizer Inc. (NYSE:PFE), Geron Corporation (NASDAQ:GERN), Cell Therapeutics (NASDAQ:CTIC), Chelsea Therapeutics International (NASDAQ:CHTP)

A US federal court yesterday invalidated Pfizer Inc.’s (NYSE:PFE) key patent covering its anti-inflammatory pill Celebrex. The patent, which was set to lapse in December 2015, would have given Pfizer an 18-month extension from the expiry of the patent for the major ingredient in the drug, celecoxib. Pfizer Inc. (NYSE:PFE) stock performance was -2.69% in last session and finished the day at $31.12. Traded volume … Continue reading Biotech Active Stocks: Pfizer Inc. (NYSE:PFE), Geron Corporation (NASDAQ:GERN), Cell Therapeutics (NASDAQ:CTIC), Chelsea Therapeutics International (NASDAQ:CHTP)

Biotech Gainers: Geron Corporation (NASDAQ:GERN), Chelsea Therapeutics International (NASDAQ:CHTP), TESARO Inc (NASDAQ:TSRO), Vanda Pharmaceuticals (NASDAQ:VNDA)

Geron Corp. (NASDAQ:GERN)‘s stock had its “positive” rating reaffirmed by equities researchers at Wells Fargo & Co. in a research report issued on Thursday, AnalystRatings.NETreports. Geron Corporation (NASDAQ:GERN) stock performance was 5.62% in last session and finished the day at $1.78. Traded volume was 16,397,352 million shares in the last session and the average volume of the stock remained 5.30 million shares. The beta of … Continue reading Biotech Gainers: Geron Corporation (NASDAQ:GERN), Chelsea Therapeutics International (NASDAQ:CHTP), TESARO Inc (NASDAQ:TSRO), Vanda Pharmaceuticals (NASDAQ:VNDA)

Hot Biotech Movers: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Insmed Incorporated (NASDAQ:INSM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) saw a significant decrease in short interest during the month of May. As of May 30th, there was short interest totalling 8,284,614 shares, a decrease of 15.5% from the May 15th total of 9,799,100 shares. Several analysts have recently commented on the stock. Analysts at Roth Capital downgraded shares of Chelsea Therapeutics International from a “buy” rating to a “neutral” … Continue reading Hot Biotech Movers: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Insmed Incorporated (NASDAQ:INSM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Wall Street Hot Runners: Molycorp Inc (NYSE:MCP), NQ Mobile (NYSE:NQ), IAMGOLD (NYSE:IAG), Magnum Hunter Resources (NYSE:MHR), Chelsea Therapeutics (NASDAQ:CHTP)

Molycorp Inc (NYSE:MCP) is said to have been downgraded to Underweight from Neutral by JPMorgan financial analysts. The JPMorgan bank downgraded Molycorp Inc (NYSE:MCP) to Underweight as soon as the company reported its Q1 results, stating that Molycorp will look for another capital raise likely this year. Molycorp Inc (NYSE:MCP) stock performance was 1.45% in last session and finished the day at $2.80. Traded volume … Continue reading Wall Street Hot Runners: Molycorp Inc (NYSE:MCP), NQ Mobile (NYSE:NQ), IAMGOLD (NYSE:IAG), Magnum Hunter Resources (NYSE:MHR), Chelsea Therapeutics (NASDAQ:CHTP)

Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

MannKind Corporation (NASDAQ:MNKD) loss of 14 cents per share in the first quarter of 2014 was wider than the Zacks Consensus Estimate by a penny but narrower than the year-ago loss by a penny. MannKind Corporation (NASDAQ:MNKD) did not generate any revenue in the first quarter of 2014, as in the year-ago quarter. Research and development (R&D) expenses remained flat at $26.2 million in the … Continue reading Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)

Some drugs that have gained approval this year so far include AstraZeneca’s Myalept (complications of leptin deficiency) and Farxiga (type II diabetes), Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) (to treat neurogenic orthostatic hypotension), BioMarin’s Vimizim (Morquio A syndrome) and Vanda Pharma’s Hetlioz. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock performance was -5.75% in last session and finished the day at $4.92. Traded volume was 3.02million shares in … Continue reading NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)